BUZZ-Corvus rises as it invests in China partner to advance skin, asthma drug trials

Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc.

CRVS

0.00

** Shares of biotech firm Corvus Pharmaceuticals CRVS.O rise 2% to $11.36 premarket

** Co invests $5 mln in Angel Pharma to support trials of soquelitinib for atopic dermatitis, a chronic skin disease causing inflammation and itching - CRVS

** Funding to also back planned asthma study; skin trial readout expected late 2026, asthma study to start early 2027, co says

** Angel Pharma, 49% owned by Corvus, is enrolling patients in China study, testing multiple doses over 12 weeks - CRVS

** Co says drug also under study in U.S. for blood cancers and skin condition

** Says investment expands exposure to China’s inflammation and immunology market

** As of last close, stock up ~45% YTD


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.